Trial reportCNS neuroscience & therapeutics2025
The Effect of Electroconvulsive and Magnetic Seizure Therapy (MST) on Cortical Thickness in Schizophrenia.
Trial report in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02746965 (Magnetic Seizure Therapy for Schizophrenia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Magnetic Seizure Therapy for Schizophrenia
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIdentifying ways to conduct brain stimulation that match the clinical efficacy of electroconvulsive therapy (ECT) without the side effects of ECT is an important goal in schizophrenia (SCS). Magnetic seizure therapy (MST) is a potential alternative, which has shown considerable efficacy but with mild cognitive impairment.
objectiveThis study compared the clinical efficacy and cognitive side effects of ECT and MST. In addition, we also investigated the possible contribution of cortical thickness changes to treatment response.
methodsThirty-four confirmed schizophrenia patients were randomly treated with ECT (n = 16) or MST (n = 18) for 4 weeks. Mental symptoms were measured through PANSS, cognition was measured through the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and changes in cortical thickness before and after treatment were compared using FreeSurfer.
resultsBoth treatments reduced the PANSS score and had comparable efficacy, while MST was superior in preserving the RBANS language score.
conclusionIn this study, neither the MST group nor the ECT group showed significant changes in cortical thickness after treatment. MST, like ECT, effectively alleviates symptoms of schizophrenia but retains cognitive function slightly better.
trial registrationClinicalTrials.gov identifier: NCT02746965.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.